The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for blockbuster treatments and substantial returns is certain, the associated risks are also notable. Many of thes